Trial · NCT00618982
Adverse events137
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 137
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Edema: Limb | Blood and lymphatic system disorders | Sorafenib (Nexavar, BAY43-9006) | 7 | 83 | |
| other | Hemoglobin | Blood and lymphatic system disorders | Sorafenib (Nexavar, BAY43-9006) | 12 | 83 | |
| other | Neutrophils | Blood and lymphatic system disorders | Sorafenib (Nexavar, BAY43-9006) | 3 | 83 | |
| other | Platelets | Blood and lymphatic system disorders | Sorafenib (Nexavar, BAY43-9006) | 7 | 83 | |
| other | Hypertension | Cardiac disorders | Sorafenib (Nexavar, BAY43-9006) | 40 | 83 | |
| other | Hypotension | Cardiac disorders | Sorafenib (Nexavar, BAY43-9006) | 3 | 83 | |
| other | Hyperthyroidism | Endocrine disorders | Sorafenib (Nexavar, BAY43-9006) | 3 | 83 | |
| other | Hypothyroidism | Endocrine disorders | Sorafenib (Nexavar, BAY43-9006) | 12 | 83 | |
| other | Dry eye | Eye disorders | Sorafenib (Nexavar, BAY43-9006) | 3 | 83 | |
| other | Ocular - Other | Eye disorders | Sorafenib (Nexavar, BAY43-9006) | 3 | 83 | |
| other | Anorexia | Gastrointestinal disorders | Sorafenib (Nexavar, BAY43-9006) | 21 | 83 | |
| other | Colitis | Gastrointestinal disorders | Sorafenib (Nexavar, BAY43-9006) | 4 | 83 | |
| other | Constipation | Gastrointestinal disorders | Sorafenib (Nexavar, BAY43-9006) | 9 | 83 | |
| other | Diarrhea | Gastrointestinal disorders | Sorafenib (Nexavar, BAY43-9006) | 53 | 83 | |
| other | Dry mouth | Gastrointestinal disorders | Sorafenib (Nexavar, BAY43-9006) | 3 | 83 | |
| other | GI - Other | Gastrointestinal disorders | Sorafenib (Nexavar, BAY43-9006) | 13 | 83 | |
| other | Gastritis | Gastrointestinal disorders | Sorafenib (Nexavar, BAY43-9006) | 3 | 83 | |
| other | Heartburn | Gastrointestinal disorders | Sorafenib (Nexavar, BAY43-9006) | 8 | 83 | |
| other | Hemorrhoids | Gastrointestinal disorders | Sorafenib (Nexavar, BAY43-9006) | 3 | 83 | |
| other | Mucositis (clinical exam), Oral cavity | Gastrointestinal disorders | Sorafenib (Nexavar, BAY43-9006) | 6 | 83 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00618982/events